IP Library › Granted Patent US 10,196,404
Granted Patent B2
US 10,196,404 · App. 15/790,660 · Granted Feb 5, 2019

MCL-1 inhibitors and methods of use thereof

Inventors: Alexander Hird (Waltham, MA); Matthew Belmonte (Waltham, MA); Wenzhan Yang (Waltham, MA); Paul Secrist (Waltham, MA); Daniel Robbins (Waltham, MA); Steven Kazmirski (Waltham, MA); Dedong Wu (Waltham, MA); Bo Peng (Waltham, MA); Jeffrey Johannes (Waltham, MA); Michelle Lamb (Waltham, MA); Qing Ye (Waltham, MA); Xiaolan Zheng (Waltham, MA)
Assignee: AstraZeneca AB
C07D497/22C07D515/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,404
App. No.
15/790,660
Granted
Feb 5, 2019
Kind
B2
Abstract

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

Claims (5)

1. A compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I)

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 .

3. The pharmaceutically acceptable salt of the compound of claim 1 .

4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, carrier or diluent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2017
From: ASTRAZENECA PHARMACEUTICALS LP
To: ASTRAZENECA UK LIMITED
Reel/Frame 044305/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2017
From: ASTRAZENECA UK LIMITED
To: ASTRAZENECA AB
Reel/Frame 044700/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2017
From: HIRD, ALEXANDER; BELMONTE, MATTHEW ALAN; YANG, WENZHAN; SECRIST, JOHN PAUL; ROBBINS, DANIEL WILLIAM; KAZMIRSKI, STEVEN LEE; WU, DEDONG; PENG, BO; JOHANNES, JEFFREY; LAMB, MICHELLE LAURAE; YE, QING; ZHENG, XIAOLAN
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 044700/0767 →
Continuity (3)
Continuation 15493210 · Apr 21, 2017
Provisional Application 62326156 · Apr 22, 2016
Related Publication 20180155362A1 · Jun 7, 2018